Seroprevalence and immune response to SARS-CoV-2 in Paris

A large working population in Paris was tested to understand the prevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection. This population, not particularly exposed to SARS-CoV-2 infection, represented active workers, as opposed to other epidemiological model studies that may underestimate infection's true prevalence.

François Anna et al. published this study in a recent medRxiv* preprint paper, where they present the results of assessing the serological response in the selected population. They tested for specific IgG response against the SARS CoV-2 Nucleoprotein and Spike protein and performed a pseudo-neutralization assay in sera of urban dwellers in Paris.

Study: High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. Image Credit: Kateryna Kon / Shutterstock
Study: High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. Image Credit: Kateryna Kon / Shutterstock

Since January 2020, this virus has spread rapidly in France, leading to a saturation of hospitals' ICUs due to the severe coronavirus disease 2019 (CODIV-19). Because of the high transmission rate, the extent of exposure to SARS-CoV-2 in the French population is poorly documented. Also, compared to the RT-qPCR (which was primarily used to detect infection), the serological study is an efficient way to monitor virus propagation.

However, employing the serological assay for large cohorts is a significant challenge, and results may not be accurate. Thus, the authors in this study developed a robust and highly sensitive method for a broad dynamic range of the measurement. These methods exceed the performance of currently marketed serological assays.

They developed two original bioluminescence-based serological assays allowing a high throughput assessment of the specific antibody responses to the Spike (S) and Nucleoprotein (N) proteins of SARS-CoV-2. They also tested the antibodies' ability to neutralize the virus fusion with a permissive human cell line.

The authors monitored individual serology against SARS-CoV-2 in a large cohort of 1847 workers in March-April 2020 - the pandemic peak in Paris and followed it up for six months.

The participants (from Institut Curie - a hospital and research center specialized in oncology) have been marginally in contact with COVID-19 patients and are domiciled in the Paris conurbation. These participants are representative of healthy, active adults from an urban area.

The study found a high prevalence of immunization but relatively short-lived responses.

Other studies across the world show variable levels of observations in seroprevalence. Among seropositive individuals, 20% of them were observed to be asymptomatic in this study. In similar study reports, the percentage of asymptomatic individuals ranged from 40% - 80%.

Based on their results, the authors further emphasized the predictive value and specificity of the anosmia (or loss of smell) / ageusia (or loss of taste) symptoms. Anosmia and ageusia were observed in 52% of the IgG-positive individuals and only 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative, suggesting that infection's true prevalence may reach 16.6%.

The authors discuss in detail the serological complexity of long-lasting immunity based on their results: the slow drop of anti-S IgG titer did not correlate with the major decrease of pseudo-neutralization activity observed (53%). The occurrence of other Ig isotypes, such as IgM or IgA, may explain the neutralization activity - in this case, in which the pseudo-neutralization assay is exclusively associated with anti-S response.

The prevalence of immunization was 11.6% (CI:10.2-13.2), considering positivity in at least one assay. Interestingly, 5% of RT-qPCR positive individuals did not show the presence of systemic IgGs. Also, among those individuals who had the antibodies, 21% were asymptomatic.

In the second sampling stage, sera obtained 4-8 weeks, anti-N and anti-S IgG titers, and pseudo-neutralization activity declined enormously with time.

Since there appears to be a gradual loss of the virus-specific IgG titer, the authors point out that their observed seroprevalence (11.6-16.6%) results may still underestimate the number of individuals who have been infected by the SARS-CoV-2. Therefore an accurate retrospective assessment is difficult to achieve - because of the fast decrease of the antibody titer. This study spotlights the fact that SARS-CoV-2 has a high prevalence in a high-density population; along with a short-lived immune response, chances of reinfection and virus persistence is too high.

Journal reference:
  • High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris, Francois Anna, Sophie Goyard, Ana Ines Lalanne, Fabien Nevo, Marion Gransagne, Philippe Souque, Delphine Louis, Veronique Gillon, Isabelle Turbiez, Francois-Clement Bidard, Aline Gobillon, Alexia Savignoni, Maude Guillot-Delost, Francois Dejardin, Evelyne Dufour, Stephane Petres, Odile Richard-Le Goff, Zaineb Choucha, Olivier Helynck, Yves L Janin, Nicolas Escriou, Pierre Charneau, Thierry ROSE, Olivier Lantz, medRxiv 2020.10.25.20219030; doi: https://doi.org/10.1101/2020.10.25.20219030, https://www.medrxiv.org/content/10.1101/2020.10.25.20219030v1
Dr. Ramya Dwivedi

Written by

Dr. Ramya Dwivedi

Ramya has a Ph.D. in Biotechnology from the National Chemical Laboratories (CSIR-NCL), in Pune. Her work consisted of functionalizing nanoparticles with different molecules of biological interest, studying the reaction system and establishing useful applications.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dwivedi, Ramya. (2020, October 30). Seroprevalence and immune response to SARS-CoV-2 in Paris. News-Medical. Retrieved on August 02, 2021 from https://www.news-medical.net/news/20201030/Seroprevalence-and-immune-response-to-SARS-CoV-2-in-Paris.aspx.

  • MLA

    Dwivedi, Ramya. "Seroprevalence and immune response to SARS-CoV-2 in Paris". News-Medical. 02 August 2021. <https://www.news-medical.net/news/20201030/Seroprevalence-and-immune-response-to-SARS-CoV-2-in-Paris.aspx>.

  • Chicago

    Dwivedi, Ramya. "Seroprevalence and immune response to SARS-CoV-2 in Paris". News-Medical. https://www.news-medical.net/news/20201030/Seroprevalence-and-immune-response-to-SARS-CoV-2-in-Paris.aspx. (accessed August 02, 2021).

  • Harvard

    Dwivedi, Ramya. 2020. Seroprevalence and immune response to SARS-CoV-2 in Paris. News-Medical, viewed 02 August 2021, https://www.news-medical.net/news/20201030/Seroprevalence-and-immune-response-to-SARS-CoV-2-in-Paris.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
SARS-CoV-2 delta variant associated with several vaccine breakthrough cases in Houston